Ursodiol: Nursing Drug Guide, Biliary Obstruction & Hold Rules
Ursodeoxycholic acid (UDCA) can protect cholestatic liver disease and dissolve selected radiolucent gallstones—but giving it when bile cannot drain, or ignoring rising AST, ALT, alkaline phosphatase, or bilirubin, can worsen biliary injury. Before every dose, confirm there is no complete biliary obstruction, no acute cholangitis or gallstone pancreatitis requiring surgery, and that liver function trends are reviewed against the patient's baseline.
Ursodiol tablet labeling contraindicates use in complete biliary obstruction. Capsule labeling excludes patients with compelling reasons for cholecystectomy—including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula. PBC labeling requires monitoring γ-GT, alkaline phosphatase, AST, ALT, and bilirubin monthly for three months then every six months; discontinue if parameters rise to clinically significant levels above stable historical values. Caution is required to maintain bile flow in all patients.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Hold ursodiol and contact the prescriber or pharmacist when imaging or symptoms suggest biliary obstruction, when LFTs climb above the patient's stable baseline on PBC therapy, or when the patient has acute cholecystitis, cholangitis, or gallstone pancreatitis listed as reasons cholecystectomy would be indicated. Never give a scheduled dose simply because it is on the MAR when the biliary pathway may be blocked.
Most common brand names
Ursodiol is the generic name for ursodeoxycholic acid (UDCA). Nurses see it on MARs as ursodiol capsules or scored tablets from multiple manufacturers.
Common U.S. products include ursodiol capsules 300 mg (gallstone dissolution and prevention indications per capsule labeling) and ursodiol tablets 250 mg and 500 mg (primary biliary cholangitis per tablet labeling). Verify formulation and indication on each order—doses are weight-based for PBC and dissolution, but gallstone prevention uses a fixed 600 mg/day regimen.
Why we give it — Indications
Ursodiol is a bile acid used in hepatobiliary disease and selected gallstones management. Indication and dosing differ between capsule and tablet prescribing information—always match the product label to the order.
| Use | Detail |
|---|---|
| Primary biliary cholangitis (PBC) | Ursodiol tablets 250 mg and 500 mg are indicated for treatment of patients with primary biliary cholangitis at 13–15 mg/kg/day in two to four divided doses with food per tablet labeling. |
| Gallstone dissolution & prevention | Capsules are indicated for radiolucent, noncalcified gallbladder stones <20 mm in selected patients at surgical risk, and for prevention of gallstone formation in obese patients experiencing rapid weight loss (600 mg/day in two divided doses). Serial abdominal ultrasound every six months during dissolution therapy per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ursodiol is a hydrophilic bile acid that replaces toxic hydrophobic bile acids in cholestatic liver disease, protects cholangiocytes and hepatocytes, and—in gallstone disease— increases cholesterol solubility in bile. It requires an intact enterohepatic circulation and patent biliary drainage to be safe and effective; when bile flow is obstructed, the same mechanism can increase biliary pressure and worsen injury—hence contraindication in complete obstruction and caution to maintain bile flow per labeling.
Dosing overview
Dosing is indication- and formulation-specific. Weight-based regimens require accurate weight and verified product strength (300 mg capsule vs 250/500 mg tablet). Dosing must be verified against current prescribing information, prescriber order, hepatic function, and local policy.
Missed dose: Not specified in the reviewed prescribing information
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption | Majority absorbed after oral dosing; incomplete absorption; ~90% of therapeutic capsule dose absorbed in small bowel per capsule labeling | Separate bile acid sequestrants and aluminum antacids that reduce absorption |
| Steady state | Bile ursodeoxycholic acid concentrations reach steady state in about 3 weeks (capsule labeling) | Do not judge PBC or dissolution failure before adequate trial and scheduled monitoring intervals |
| Duration after stop | After stopping, bile ursodiol falls to ~5–10% of steady-state level in about 1 week (capsule labeling) | Stone recurrence may occur after discontinuation—plan ultrasound surveillance per labeling |
| Half-life | Not specified in the reviewed prescribing information as a single nursing summary value | Enterohepatic cycling and hepatic extraction dominate; worsening cholestasis may reduce extraction per tablet pharmacokinetics section |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, formulation, and weight-based dose; complete medication reconciliation for bile acid sequestrants and lipid drugs
- Review biliary imaging and symptoms—hold if complete obstruction, cholangitis, gallstone pancreatitis, or acute cholecystitis is suspected
- Compare current liver function tests to baseline; screen bile acid sequestrants and aluminum antacids that reduce absorption
Contraindications
- Complete biliary obstruction (tablet labeling); capsule labeling also excludes calcified/radiopaque stones and patients with compelling need for cholecystectomy
- Acute biliary disease requiring surgery—unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, biliary-GI fistula (capsule labeling)
- Known hypersensitivity or intolerance to ursodiol or any formulation component; allergy to bile acids (capsule labeling)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Bile acid sequestrants (cholestyramine, colestipol) | Reduce ursodiol absorption by binding bile acids in the gut | Separate administration by several hours per prescriber/pharmacy guidance; document timing on MAR |
| Aluminum-based antacids | Adsorb bile acids in vitro; expected to reduce ursodiol absorption similarly to sequestrants | Space antacid and ursodiol doses; notify pharmacist when both are ordered |
| Estrogens, oral contraceptives, clofibrate (and other lipid-altering drugs) | Increase hepatic cholesterol secretion and may encourage gallstone formation, counteracting dissolution therapy | Screen at admission reconciliation; notify prescriber if new estrogen or lipid drug starts during dissolution therapy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsule or tablet swallowed with water; PBC labeling specifies administration with food in two to four divided doses.
- Give with food for PBC regimens; if nausea occurs, confirm spacing from cholestyramine/colestipol and aluminum antacids
- 500 mg scored tablets may be broken in half per labeling—segments taste bitter; swallow unchewed with water and store halves separately up to 28 days
- Do not crush capsules unless pharmacy provides an approved method; verify 300 mg capsule vs 250/500 mg tablet strength before administration
Labeling cautions that bile flow must be maintained during ursodiol therapy. If obstructive gastrointestinal symptoms occur—especially in patients with intestinal stenosis or stasis—hold ursodiol until evaluation for enteroliths (bezoars) per postmarketing warnings.
Expected therapeutic response
- PBC: gradual improvement in alkaline phosphatase, bilirubin, and other hepatic biochemistries over months per clinical studies in tablet labeling
- Gallstone dissolution: partial or complete stone dissolution on serial ultrasound—partial dissolution by 6 months predicts higher eventual success
- Gallstone prevention during rapid weight loss: reduced incidence of new stones versus placebo in labeling trials at 600 mg/day
Red flags — Stop and act
Stop and escalate when biliary obstruction, infection, or clinically significant hepatic deterioration appears—ursodiol is not a substitute for biliary decompression or cholecystectomy when those are indicated.
- Fever, rigors, or persistent RUQ abdominal pain with rising bilirubin—possible cholangitis; hold ursodiol and urgent biliary evaluation
- Confirmed or suspected complete biliary obstruction on imaging—contraindication to ursodiol per labeling
- Acute gallstone pancreatitis or unremitting cholecystitis—patient is not a capsule dissolution candidate; surgical pathway per labeling
- Clinically significant rise in AST, ALT, alkaline phosphatase, or jaundice above stable baseline on PBC therapy—consider discontinuation per tablet warnings
- Obstructive GI symptoms (vomiting, distension) in patients with intestinal stenosis or stasis—hold for enterolith evaluation
Common and serious adverse effects
Diarrhea and GI symptoms are common in gallstone trials; PBC labeling lists additional hepatic and skin reactions. Distinguish expected GI tolerance from obstruction or treatment failure.
| Adverse effect | Frequency / notes | Nursing response |
|---|---|---|
| Diarrhea | ~21–27% in gallstone dissolution trials; ~25% in prevention trials (labeling tables) | Supportive care, hydration, skin protection; notify prescriber if severe or dehydrating |
| Abdominal pain / dyspepsia | Common in dissolution trials; may overlap with biliary obstruction symptoms | Assess pattern, fever, LFT trends—do not assume all pain is benign drug effect |
| Nausea / vomiting | Reported across indications | Monitor intake; evaluate for obstruction if persistent with distension |
| Pruritus / rash / alopecia | Listed in PBC postmarketing experience | Differentiate from worsening cholestasis; report widespread rash or angioedema |
| Worsening LFTs / jaundice | Postmarketing hepatic enzyme increases; treatment discontinuation criteria in PBC labeling | Hold and notify prescriber when values exceed stable baseline thresholds |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and antidote
Capsule labeling states neither accidental nor intentional overdosing has been reported; doses of 16–20 mg/kg/day were tolerated up to 37 months without symptoms in seven patients. The most likely manifestation of severe overdose would probably be diarrhea, treated symptomatically.
Management
- No specific antidote is listed in the reviewed prescribing information
- Supportive care for diarrhea, dehydration, and abdominal symptoms
- Contact local poison control or medical toxicology services per facility protocol if ingestion is substantial or symptoms are severe
- Document all ursodiol sources and hold further doses until advised
Look-alike / sound-alike and error prevention
No specific look-alike/sound-alike pair was identified in the reviewed sources, but standard medication-name verification still applies.
- Ursodiol vs ursodeoxycholic acid vs UDCA—confirm same active moiety on label and MAR
- 300 mg capsule vs 250/500 mg tablet—different indications; independent double-check weight-based math
- Half-tablet scoring—500 mg tablet segments look like full tablets; verify calculated mg dose
- Chenodiol historical confusion—older gallstone bile acid; verify current order is ursodiol
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food | PBC regimens: give with food in divided doses per tablet labeling |
| Sequestrant spacing | Hold cholestyramine/colestipol and aluminum antacids away from ursodiol per pharmacy |
| Scored tablets | Break 500 mg tabs at score; swallow unchewed; store halves separately up to 28 days |
| Ultrasound timing | Dissolution: imaging every 6 months first year; confirm clearance 1–3 months after apparent dissolution |
| Commonly missed | Continuing ursodiol during workup for ductal obstruction or rising LFTs from baseline |
| Ask pharmacy when | Weight change requires dose recalculation, formulation switch, or interaction spacing questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Primary biliary cholangitis / cirrhosis risk | Requires scheduled LFT monitoring; treatment failure may present as rising bilirubin despite therapy—coordinate with hepatology |
| Post-bariatric or rapid weight-loss patients | Prevention dose 600 mg/day; high diarrhea rates—monitor hydration and electrolytes |
| Intestinal stenosis, Crohn disease, enteroanastomoses | Postmarketing enterolith (bezoar) reports—hold and evaluate obstructive symptoms |
| Pregnancy | Capsule labeling states drug is not recommended during pregnancy; animal data at high multiples of human dose showed some fertility effects. Tablet labeling reports no identified major birth defect risk from published human data but confirms benefit-risk with prescriber. |
| Lactation | Ursodiol is naturally present in human milk per tablet labeling; reports of harm in breastfed infants are extremely limited. Use caution and coordinate with prescriber—capsule labeling advises caution when nursing. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- LFT panel (AST, ALT, alkaline phosphatase, γ-GT, bilirubin) per indication-specific schedule in labeling
- Gallstone dissolution: abdominal ultrasound every 6 months first year, then confirm dissolution 1–3 months after stones appear dissolved
- GI tolerance (diarrhea, abdominal pain), pruritus, rash, and signs of biliary infection or obstruction
Document
- Indication, weight-based dose, formulation strength, and food timing with each administration
- Baseline and trend LFT values; hold events and prescriber notification when obstruction suspected
- Spacing from bile acid sequestrants/antacids and patient teaching on diarrhea and when to seek urgent care
Patient teaching
- Take ursodiol exactly as prescribed with food when ordered that way; do not skip doses to stop diarrhea without prescriber advice
- Report severe or persistent abdominal pain, fever, yellowing skin or eyes, dark urine, or pale stools immediately
- Separate cholestyramine, colestipol, and aluminum antacid doses from ursodiol by the interval pharmacy provides
- Gallstone dissolution requires long-term therapy and repeat ultrasound—stones may recur after stopping ursodiol; report diarrhea that causes dehydration
- Half-tablets from 500 mg scored tablets taste bitter—swallow promptly with water and store separated from whole tablets
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected or confirmed complete biliary obstruction, cholangitis, biliary-gastrointestinal fistula, or gallstone pancreatitis
- Unremitting acute cholecystitis or other compelling indication for cholecystectomy per capsule labeling
- LFT rise to clinically significant levels above the patient's stable baseline on PBC therapy pending prescriber review
- New calcified gallstones or gallbladder nonvisualization during dissolution therapy—predicts failure; discontinue per labeling
- Obstructive GI symptoms in patients at risk for enteroliths until clinical evaluation is completed
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ursodiol crosses outpatient hepatology, bariatric, and med-surg units. Nurses bridge MAR administration with biliary imaging, LFT trends, and absorption interactions that pharmacy often clarifies.
1. Check-before-you-give protocol
- Patent biliary tree on most recent imaging when obstruction was previously questioned
- Today's LFT trends compared with documented baseline—not just "within lab reference range"
- No fever, rigors, worsening RUQ pain, or new jaundice
- Bile acid sequestrant and antacid doses spaced per pharmacy plan
2. High-alert and safety badge
Not on standard high-alert listsUrsodiol is not listed as a universal high-alert medication, but biliary obstruction contraindication and LFT monitoring make verification before every dose a high-stakes nursing task.
3. Clinical workflow: hold and question rules
- Radiology flag of ductal dilation or obstruction triggers automatic hold pending prescriber review
- Pharmacy verifies weight-based dose when tablets are halved or capsules switched
- Hepatology clinic LFT schedules—ensure inpatient doses are not given during acute obstruction workup
4. Critical teach-back questions
- “What symptoms mean you should stop taking ursodiol and call your clinician right away?” High fever with severe belly pain, yellow skin or eyes, or worsening pain after eating fatty foods.
- “Why must cholestyramine be taken at a different time from ursodiol?” It binds bile acids and can prevent ursodiol absorption if taken too close together.
5. Care coordination
Prescriber / hepatology: Interpret LFT trends, ultrasound results, and whether dissolution or PBC therapy should continue, pause, or stop.
Pharmacist: Dose calculation by weight, sequestrant spacing, formulation changes, and interaction screening.
🧠 Quick mental checklist
- Is bile actually draining, or is obstruction being worked up right now?
- Are LFTs trending up from this patient's own baseline?
- Is this the correct indication and formulation strength on the MAR?
- Did the patient take cholestyramine or aluminum antacid within the required window?
- For dissolution: is ultrasound monitoring scheduled and are stones still radiolucent?
Ursodiol NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for ursodiol using a tabbed hepatobiliary case (MAR · Labs · History · Nursing notes) focused on biliary obstruction and LFT monitoring, then work through priority action, SATA cue recognition, trend SATA, matrix urgency sorting, clinical judgment MCQ, and a contraindication cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Unfolding case. Elena is a 58-year-old with primary biliary cholangitis on ursodiol 500 mg PO three times daily with meals for 8 months. Over 48 hours she developed RUQ pain after a fatty meal, dark urine, and mild scleral icterus. Labs show rising ALP and bilirubin from her documented baseline; ultrasound notes common bile duct dilation. Cholestyramine was given at 0700; ursodiol is due at 0800. Review the case tabs before administering.
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Ursodiol 500 mg PO — three times daily with meals (PBC)
- Cholestyramine 4 g PO nightly — active
- Multivitamin PO daily
- Baseline (3 mo ago): AST 42 U/L, ALT 38 U/L, ALP 210 U/L, bilirubin 1.0 mg/dL
- Today: AST 96 U/L, ALT 88 U/L, ALP 412 U/L, total bilirubin 2.6 mg/dL
- γ-GT pending; abdominal ultrasound ordered—common bile duct 8 mm (prior 4 mm)
- 58-year-old with primary biliary cholangitis on ursodiol 8 months
- Reports 2 days of RUQ pain after fatty meal and dark urine
- No prior biliary surgery; no fever documented yet
- Weight 62 kg — dose verified at 13 mg/kg/day
- 0730: Patient rated RUQ pain 6/10; mild scleral icterus noted
- 0745: Cholestyramine given at 0700; ursodiol due at 0800
- 0750: Patient asks why ursodiol continues when "liver numbers are up"
Answer key & rationale
Frequently asked questions
When must a nurse hold ursodiol because of biliary obstruction?
Hold when complete biliary obstruction is present or suspected—tablet labeling lists complete obstruction as a contraindication. Capsule labeling excludes patients with cholangitis, biliary obstruction, gallstone pancreatitis, and other acute biliary conditions where cholecystectomy would be indicated. Confirm with prescriber and pharmacist before any dose when ductal dilation, rising bilirubin, or acute RUQ pain suggests blocked bile flow.
How often should liver function tests be monitored on ursodiol for PBC?
Tablet labeling directs monitoring γ-GT, alkaline phosphatase, AST, ALT, and bilirubin every month for three months after starting therapy, then every six months thereafter. Treatment discontinuation should be considered if values increase to clinically significant levels above stable historical baselines.
What is the usual adult dose of ursodiol for primary biliary cholangitis?
Ursodiol tablets are dosed at 13 to 15 mg/kg/day in two to four divided doses with food for PBC. The 500 mg scored tablet may be broken in half to achieve the calculated dose; halves taste bitter and should be swallowed unchewed with water.
What adverse effects should nurses expect and teach patients about?
Diarrhea is among the most common adverse effects in gallstone trials (roughly 21–27% with active drug in labeling tables). Postmarketing and PBC labeling also list abdominal pain, nausea, pruritus, rash, and alopecia. Worsening jaundice or LFTs may signal obstruction or treatment failure—not routine side effects.
Can cholestyramine be taken at the same time as ursodiol?
No. Both capsule and tablet labeling state bile acid sequestrants such as cholestyramine and colestipol interfere with ursodiol by reducing absorption. Separate doses per pharmacy guidance and document spacing on the MAR.
Is there an antidote for ursodiol overdose?
Capsule labeling reports no accidental or intentional overdoses; the most likely manifestation of severe overdose would probably be diarrhea treated symptomatically. Tablet labeling reports no overdose cases in humans; animal data describe high-dose tolerance. No specific antidote is listed—management is supportive per poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Ursodiol tablets, 250 mg and 500 mg — Full prescribing information (primary biliary cholangitis). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb79b62a-b450-4d7a-be28-5ee4d174fd58
-
U.S. National Library of Medicine. Ursodiol capsules, USP 300 mg — Full prescribing information (gallstone dissolution and prevention). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2605f6a-b72d-4773-8d2c-39acfe81e424
-
U.S. National Library of Medicine. Ursodiol tablets — Clinical pharmacology and dosage (section 12). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb79b62a-b450-4d7a-be28-5ee4d174fd58#section-12
-
U.S. National Library of Medicine. Ursodiol capsules — Contraindications and warnings. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2605f6a-b72d-4773-8d2c-39acfe81e424
-
U.S. National Library of Medicine. Ursodiol tablets — Warnings and precautions (abnormal LFTs, enteroliths). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb79b62a-b450-4d7a-be28-5ee4d174fd58
-
U.S. National Library of Medicine. Ursodiol capsules — Dosage and administration (gallstone dissolution and prevention). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2605f6a-b72d-4773-8d2c-39acfe81e424
-
U.S. National Library of Medicine. Ursodiol tablets — Drug interactions (bile acid sequestrants, antacids). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb79b62a-b450-4d7a-be28-5ee4d174fd58
-
U.S. National Library of Medicine. Ursodiol capsules — Overdosage. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2605f6a-b72d-4773-8d2c-39acfe81e424
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.